CRBP: CRB-913 achieved 5% weight loss in 12 weeks with favorable safety, supporting further clinical development
CANYON-1 phase I-B results show CRB-913, a peripherally restricted CB1 inverse agonist, achieved 5% placebo-adjusted weight loss in 12 weeks with a favorable safety profile and no severe psychiatric or GI events. Efficacy was comparable to oral GLP-1s, supporting further development and combination…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.